Britain and America have announced a landmark commercial pact that will keep zero levies on UK medicine exports entering the American market.
The Terms of the Accord
Under the terms of the agreement, the UK has committed to boost funding on drugs through the public health system. This move guarantees that tariffs on these vital goods will stay at zero for a period of 36 months.
This deal follows previous warnings to dramatically increase tariffs on branded pharmaceutical products, with figures discussed reaching 100%.
"This agreement between the United Kingdom bolsters the global environment for cutting-edge drugs and brings long-overdue equity to American-British pharmaceutical trade," a release said.
Trade Impact
Drugs represent one of the UK's biggest export categories to the United States, which is clearly the biggest buyer for leading British pharmaceutical firms.
Export figures show that in the year leading up to the third quarter, the UK shipped drugs valued at over eleven billion pounds to the US. This value represented nearly one-fifth of British export trade in that period.
"This agreement safeguards employment, boosts investment and facilitates the UK to emerge as a global hub for medical research," a government official stated.
Key NHS Changes
The pact entails several notable changes from the British government:
- Higher Cost Ceiling: The UK will raise the cost ceiling at which it deems new therapies to be unaffordable by a quarter.
- Increased NHS Spending: There is a target to raise total NHS spending on treatments from 0.3% of Gross Domestic Product to 0.6% over the following ten-year period.
- Rebate Cap: The amount drug companies must refund to the NHS to control costs will be limited at 15%. Previously, repayments exceeded 20%.
Recent Tensions
The pact follows a ongoing dispute between the pharmaceutical industry and the UK government over medicine costs and approval rates.
This friction were heightened by assertions that American consumers were paying a premium for the equivalent treatments than patients in the UK and Europe.
Over the last 18 months, several large pharmaceutical investments in the UK have been delayed or cancelled, while multi-billion-dollar expansions have been announced toward American operations.
One official publicly accepted that the NHS needed to increase expenditure on medicines, noting that its spending on drugs had declined as a percentage of its resources over the past decade.
